OptimizeRx Corporation OPRX R2K
Healthcare · Health Information Services · United States
OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.
READ MORE ›$5.19
-57.25% 1Y
Market & Price
Market Cap
$97.39M
Current Price
$5.19
High / Low (52W)
$21.68 / $4.83
Beta
1.19
Valuation
Stock P/E
14.42
Industry PE
23.65
Forward P/E
4.91
PEG Ratio
1.61
Book Value
$6.84
Price to Book
0.76
P/S
0.91
EV/EBITDA
5.35
Dividend Yield
-
Profitability & Returns
ROCE
7.87%
ROE
5.56%
ROA
5.43%
Profit Margin
6.37%
Op Margin
2.00%
EPS (Latest Qtr)
$-0.03
EPS (TTM)
$0.36
Balance Sheet & Liquidity
Debt/Equity
0.18
Quick Ratio
5.07
Current Ratio
5.37
Debt
$23.72M
Total Assets
$176.92M
Current Assets
$64.72M
Working Capital
$43.45M
Ownership
Promoter Holding
11.81%
Chg in Prom Hold
-
FII / Inst Holding
76.46%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$100.94M
Total Revenue (TTM)
$107.34M
EBITDA
$18.86M
Free Cash Flow
$11.35M
Operating Cash Flow
$14.38M
Shares Outstanding
18.77M
Gross Margin
70.04%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
20.56%
Profit 5Y
48.29%
Revenue (YoY)
-9.50%
Earnings (YoY)
-
PROS
- Compounding revenue at 20.6% over 5 years.
- Profit CAGR of 48.3% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 76.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OPRX OptimizeRx Corporation R2K | 5.19 | 14.42 | $97.39M | - | 7.87% | 5.56% | 20.56% | 48.29% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.23M | 1.29M | 1.43M | 1.82M | 1.49M | 1.71M | 2.01M | 1.76M | 1.91M | 1.79M | 2.15M | 2.87M | 3.10M | 4.11M | 5.10M | 5.42M | 5.21M | 7.01M | 5.00M | 7.58M | 8.78M | 10.52M | 11.23M | 13.63M | 16.12M | 13.73M | 13.98M | 15.09M | 13.00M | 13.82M | 16.33M | 19.69M | 18.81M | - | - | 21.93M | 29.20M | 26.07M | 32.24M | 19.84M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.58M | 10.56M | 8.55M | 8.14M | 4.91M |
| Gross Profit | 843.89K | 728.02K | 696.67K | 861.09K | 731.11K | 823.13K | 962.99K | 866.74K | 990.47K | 1.06M | 770.34K | 1.26M | 1.40M | 2.10M | 2.86M | 3.15M | 3.63M | 4.32M | 3.02M | 4.34M | 5.14M | 6.01M | 6.12M | 8.04M | 9.08M | 8.10M | 8.99M | 9.42M | 7.43M | 7.83M | 9.80M | 12.20M | 11.70M | - | - | 13.34M | 18.64M | 17.52M | 24.10M | 14.93M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.45M | 15.45M | 15.47M | 15.16M | 14.54M |
| Operating Income | -141.61K | -762.20K | -199.86K | -294.85K | -111.50K | -157.53K | 87.57K | -361.83K | -602.51K | -249.22K | -890.44K | -370.56K | -629.66K | -191.20K | 273.60K | 223.18K | 132.16K | 480.04K | -1.99M | -2.26M | -1.06M | -176.72K | -638.31K | 340.14K | 38.19K | -3.76M | -3.91M | -3.76M | -7.06M | -4.85M | -3.55M | -5.03M | -3.75M | - | - | -2.10M | 3.19M | 2.05M | 8.94M | 396.00K |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -881.00K | 4.39M | 3.28M | 9.79M | 1.57M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.30M | 1.60M | 1.15M | 1.24M | 1.16M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.27M | 1.71M | 1.05M | 7.47M | -644.00K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.07M | 181.00K | 270.00K | 2.45M | -149.00K |
| Net Income | -411.73K | -762.10K | -199.44K | -294.54K | -111.20K | -157.22K | 87.94K | -351.92K | -591.93K | -242.58K | -882.68K | -361.50K | -622.79K | -189.18K | 280.51K | 244.93K | 6.53K | 406.62K | -1.57M | -2.20M | -1.08M | -282.89K | -637.38K | 352.10K | 39.89K | -3.76M | -3.88M | -3.47M | -6.40M | -4.16M | -2.87M | -6.90M | -4.01M | - | - | -2.20M | 1.53M | 779.00K | 5.02M | -495.00K |
| Diluted EPS | - | - | - | - | - | - | 0.00 | - | - | - | - | -0.04 | -0.06 | -0.02 | 0.02 | 0.02 | 0.00 | 0.03 | -0.11 | -0.15 | -0.07 | -0.02 | -0.04 | 0.02 | 0.00 | -0.21 | -0.21 | -0.19 | -0.37 | -0.24 | -0.17 | -0.38 | -0.22 | - | - | -0.12 | 0.08 | 0.04 | 0.26 | -0.03 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.25M | - | - | - | 3.40M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 62.45M | 71.52M | 92.13M | 109.43M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 23.48M | 28.62M | 32.75M | 35.83M |
| Gross Profit | - | - | 1.87M | 2.82M | 3.28M | 3.60M | 4.34M | 5.95M | 12.21M | 15.44M | 24.11M | - | 38.97M | 42.90M | 59.38M | 73.59M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 51.26M | 60.42M | 65.59M | 61.53M |
| Operating Income | -1.85M | -1.45M | -454.92K | -267.54K | -1.03M | -597.41K | -1.58M | -2.13M | 180.13K | -3.69M | -2.14M | - | -12.29M | -17.52M | -6.22M | 12.06M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -9.42M | -21.31M | -8.90M | 16.57M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 1.45M | 6.16M | 5.29M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -11.44M | -25.16M | -19.39M | 6.95M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | 0 | -7.60M | 725.00K | 1.82M |
| Net Income | - | -2.12M | -454.55K | -267.29K | -1.03M | -595.14K | -1.54M | -2.10M | 226.34K | -3.14M | -2.21M | - | -11.44M | -17.57M | -20.11M | 5.13M |
| Diluted EPS | - | - | - | - | - | - | - | -0.21 | 0.02 | -0.23 | -0.15 | - | -0.64 | -1.03 | -1.10 | 0.27 |
| R&D Expense | - | - | - | - | - | - | - | - | 0 | 1.60M | 0 | - | - | - | 0 | 0 |
Compounded Sales Growth
| 5 Years: | 20.56% |
| 1 Year: | -9.50% |
Compounded Profit Growth
| 5 Years: | 48.29% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -57.25% |
| 6 Months: | -66.28% |
| 3 Months: | -31.53% |
| 1 Month: | -15.47% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 3.75M | 2.89M | 2.18M | 3.95M | 7.03M | 12.31M | 11.48M | 9.76M | 25.05M | 56.64M | 60.33M | - | 134.65M | 183.37M | 171.17M | 176.92M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 98.58M | 54.33M | 53.97M | 64.72M |
| Cash & Equivalents | 1.28M | 959.17K | 284.26K | 1.12M | 3.45M | 8.21M | 7.03M | 5.12M | 8.91M | 18.85M | 10.52M | - | 18.21M | 13.85M | 13.38M | 23.36M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 22.16M | 36.25M | 38.21M | 37.75M |
| Total Liabilities | 1.85M | 1.30M | - | - | - | - | - | 3.54M | 6.60M | 11.78M | 10.35M | - | 8.54M | 56.82M | 54.17M | 48.62M |
| Current Liabilities | 854.83K | 1.30M | 770.52K | 2.28M | 2.42M | 3.37M | 3.67M | 3.54M | 4.23M | 6.11M | 10.03M | - | 8.40M | 17.88M | 18.65M | 21.26M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.23M | 30.82M | 21.42M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | 234.43K | 36.82M | 33.19M | 26.10M |
| Total Equity | 1.89M | 1.59M | 1.40M | 1.67M | 4.61M | 8.94M | 7.81M | 6.22M | 18.46M | 44.86M | 49.97M | - | 126.11M | 126.55M | 117.00M | 128.29M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 18.29M | 19.90M | 20.19M | 20.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.31M | -521.51K | -624.03K | 1.13M | -56.35K | 515.11K | -465.96K | -1.48M | 792.55K | -1.66M | -6.31M | - | 10.65M | -7.24M | 4.89M | 18.71M |
| Investing Cash Flow | -225.64K | -239.92K | -50.87K | -298.65K | -409.95K | -100.96K | -349.54K | -42.24K | -5.69M | -10.58M | -124.72K | - | -58.18M | -25.34M | -450.00K | 68.00K |
| Financing Cash Flow | 2.16M | 442.50K | 0 | 0 | 2.80M | 4.35M | -357.42K | -390.00K | 8.69M | 22.18M | -1.90M | - | -18.95M | 28.22M | -4.91M | -8.80M |
| Capital Expenditure | 1.23K | -13.10K | -2.23K | -0 | -6.98K | -2.05K | -178.43K | -42.24K | -34.36K | -87.72K | -68.04K | -486.00K | -244.56K | -871.00K | -450.00K | - |
| Free Cash Flow | -1.31M | -534.61K | -626.26K | 1.13M | -63.33K | 513.06K | -644.40K | -1.52M | 758.19K | -1.75M | -6.38M | - | 10.41M | -8.11M | 4.44M | 18.71M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -66.47M | -4.36M | -472.00K | 9.98M |
| Share Buybacks | - | - | - | - | - | - | 806.91K | 390.00K | - | - | - | - | 20.02M | 7.52M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | 62.4% | 60.0% | 64.5% | 67.3% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | -19.7% | -24.5% | -6.7% | 11.0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | -18.3% | -24.6% | -21.8% | 4.7% |
| ROE % | - | -133.5% | -32.4% | -16.0% | -22.2% | -6.7% | -19.7% | -33.8% | 1.2% | -7.0% | -4.4% | - | -9.1% | -13.9% | -17.2% | 4.0% |
| ROCE % | -63.8% | -91.5% | -32.4% | -16.0% | -22.3% | -6.7% | -20.2% | -34.2% | 0.9% | -7.3% | -4.2% | - | -9.7% | -10.6% | -4.1% | 7.7% |
Shareholding Pattern
Insiders
11.81%
Institutions
76.46%
Public Float
86.70%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Whetstone Capital Advisors, LLC | 12.47% | 1.51M | $7.83M |
| 2 | Blackrock Inc. | 9.62% | 1.16M | $6.04M |
| 3 | Royce & Associates LP | 7.34% | 888.03K | $4.61M |
| 4 | Parkman Healthcare Partners LLC | 6.03% | 729.37K | $3.79M |
| 5 | Vanguard Capital Management LLC | 5.67% | 685.45K | $3.56M |
| 6 | Kennedy Capital Management, LLC | 5.43% | 656.26K | $3.41M |
| 7 | BLAIR WILLIAM & CO/IL | 5.08% | 614.99K | $3.19M |
| 8 | Rice, Hall, James & Associates LLC | 4.98% | 601.92K | $3.12M |
| 9 | Dimensional Fund Advisors LP | 4.66% | 563.57K | $2.92M |
| 10 | State Street Corporation | 3.95% | 477.78K | $2.48M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OPRX
No recent headlines available.